Profile data is unavailable for this security.
About the company
Lipum AB (publ) is a Sweden-based biopharmaceutical company specialized in discovery and development of new treatment for chronic inflammatory diseases. Lipum develops new biological medicine for treatment of chronic inflammatory diseases eg rheumatoid arthritis. Development is based on results from preclinical research, for example in well-established animal models for inflammatory arthritis. The prospective drug is an antibody directed against a new target molecule, the protein Bile Salt-Stimulated Lipase (BSSL). Lipum's antibody (SOL-116) has a different mechanism of action than the other drugs. Lipum's drug candidate SOL-116 is a humanized monoclonal antibody and is therefore categorized as a biological drug.
- Revenue in SEK (TTM)0.00
- Net income in SEK-39.24m
- Incorporated2010
- Employees5.00
- LocationLipum AB (publ)Tvistevagen 48CUMEA 907 36SwedenSWE
- Phone+46 903403430
- Websitehttps://lipum.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elicera Therapeutics AB | 12.07m | -20.79m | 69.31m | 2.00 | -- | 2.68 | -- | 5.74 | -0.9137 | -0.9137 | 0.5059 | 0.7377 | 0.3224 | -- | 12.85 | 6,035,610.00 | -55.51 | -40.06 | -79.82 | -49.74 | -- | -- | -172.21 | -415.41 | -- | -- | 0.00 | -- | 777.23 | -- | 15.64 | -- | -- | -- |
| Oncozenge AB | 0.00 | -11.78m | 107.88m | -- | -- | 7.59 | -- | -- | -1.01 | -1.01 | 0.00 | 1.21 | 0.00 | -- | -- | -- | -55.08 | -- | -59.44 | -- | -- | -- | -- | -- | -- | -2,944.50 | 0.00 | -- | -- | -- | 65.91 | -- | -- | -- |
| Lipidor AB | 87.00k | -13.53m | 113.88m | -- | -- | 6.77 | -- | 1,308.93 | -0.1505 | -0.1505 | 0.0009 | 0.0207 | 0.005 | -- | 0.1843 | -- | -77.12 | -59.41 | -178.11 | -75.10 | -- | -- | -15,550.58 | -643.36 | -- | -- | 0.00 | -- | 73.33 | -20.33 | 72.24 | -- | -- | -- |
| Pila Pharma AB | 1.03m | -6.92m | 130.21m | 0.00 | -- | 44.35 | -- | 125.92 | -0.3165 | -0.3165 | 0.049 | 0.1082 | 0.2602 | -- | 8.21 | 1,034,020.00 | -174.06 | -108.88 | -276.40 | -121.45 | -406.94 | -42.67 | -668.94 | -1,577.64 | -- | -163.35 | 0.00 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| Vivesto AB | 0.00 | -98.92m | 138.55m | 4.00 | -- | 0.7737 | -- | -- | -0.1839 | -0.1839 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -39.70 | -- | -43.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | 64.80 | -- | -- | -- |
| Corline Biomedical AB | 17.55m | -6.46m | 171.50m | 14.00 | -- | 1.96 | -- | 9.77 | -0.3005 | -0.3005 | 0.8165 | 4.07 | 0.1729 | -- | 4.69 | 1,349,769.00 | -6.36 | -5.71 | -7.13 | -6.24 | 141.25 | 128.60 | -36.80 | -38.46 | -- | -306.52 | 0.00 | -- | 6.28 | 74.14 | -177.67 | -- | 62.51 | -- |
| Enorama Pharma AB | 5.87m | -41.41m | 181.83m | 5.00 | -- | 6.15 | -- | 30.98 | -0.9211 | -0.9211 | 0.1295 | 0.6408 | 0.1413 | 1.20 | 2.94 | 1,173,800.00 | -99.66 | -73.56 | -147.35 | -104.85 | -32.71 | 43.36 | -705.54 | -557.42 | 2.00 | -29.36 | 0.0094 | -- | -80.17 | -23.71 | -6.15 | -- | -- | -- |
| Lipum AB (publ) | 0.00 | -39.24m | 307.58m | 5.00 | -- | 6.44 | -- | -- | -3.17 | -3.17 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -92.41 | -127.85 | -120.33 | -184.50 | -- | -- | -- | -293,228.70 | -- | -328.75 | 0.1979 | -- | -- | -- | 2.38 | -- | -- | -- |
| Dicot Pharma AB | 233.09k | -50.94m | 373.54m | 3.00 | -- | 13.38 | -- | 1,602.57 | -0.0505 | -0.0505 | 0.0002 | 0.0157 | 0.0054 | 9.26 | 0.079 | 77,696.66 | -117.97 | -- | -144.43 | -- | -19,313.23 | -- | -21,855.92 | -- | 1.98 | -- | 0.00 | -- | 89.43 | -- | -39.05 | -- | -- | -- |
| Orexo AB | 595.80m | -105.30m | 378.35m | 113.00 | -- | -- | -- | 0.635 | -3.05 | -3.05 | 17.28 | -0.7896 | 0.7609 | 1.17 | 2.32 | 5,136,207.00 | -13.45 | -6.41 | -20.81 | -9.99 | 88.28 | 86.76 | -17.67 | -11.83 | 1.47 | -0.7557 | 1.05 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Navamedic ASA | 530.94m | 24.07m | 396.87m | 45.00 | 16.49 | 1.64 | 10.19 | 0.7475 | 1.39 | 1.39 | 31.30 | 14.00 | 1.08 | 3.60 | 4.21 | 12,077,510.00 | 4.91 | 0.039 | 7.35 | 0.0635 | 40.04 | 38.33 | 4.53 | 0.038 | 0.8753 | 3.63 | 0.3686 | -- | 33.98 | 22.72 | -88.77 | -2.53 | 59.60 | -- |
| Enzymatica AB (publ) | 44.95m | -55.95m | 436.92m | 16.00 | -- | 4.80 | -- | 9.72 | -0.309 | -0.309 | 0.2485 | 0.3747 | 0.3461 | 1.19 | 8.20 | 2,497,333.00 | -43.08 | -27.36 | -45.77 | -33.98 | 63.99 | 65.08 | -124.47 | -66.12 | -- | -24.43 | 0.2789 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
Data as of Nov 05 2024. Currency figures normalised to Lipum AB (publ)'s reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 30 Sep 2024 | 4.73k | 0.02% |
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
